Subcutaneous Recombinant Interleukin-2 Plus Chemotherapy with Cisplatin and Dacarbazine in Metastatic Melanoma

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 730-733

  Guida, M ^a   Latorre, A ^a   Mastria, A ^a   De Lena, M ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

CDDP + DTIC + subcutaneous IL 2; Metastatic melanoma

Indexed keywords

CISPLATIN; DACARBAZINE; DEXAMETHASONE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPOTENSION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LUNG EDEMA; MALE; MELANOMA; METASTASIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0029931061     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00662-1     Document Type: Article

References (15)

1. Legha SS. Current therapy for malignant melanomas. Semin Oncol 1989, 16 (Suppl. 1), 34-44.
2. De Prete SA, Maurer LH, O'Donnel J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984, 68, 1403-1405.
3. De Lena M, Lorusso V, Guida M. Interleukin-2: Biological, Pharmacological, and Clinical Aspects. Milano, Masson, 1992.
4. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992, 10, 180-199.
5. Atzpodien MJ, Korfen A, Franks CR, et al. Home therapy with recombinant interleukin-2 and interferon-2b in advanced human malignancies. Lancet 1990, 335, 1509-1512.
6. Guida M, Latorre A, Casamassima A, et al. Subcutaneous rIL-2 in advanced melanoma and kidney carcinoma: clinical and biological aspects. In Bergmann L, Mitron PS, eds. Contributions in Oncology Cytokines in Cancer Therapy. Basel, Karger, 1994, 182-190.
7. De Lena M, Guida M, Casamassima A, et al. Subcutaneous rIL-2 in advanced melanoma and kidney carcinoma. Int J Oncol 1992, 1, 181-189.
8. Richards JM, Gilewski TA, Ramming K, et al. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992, 69, 427-429.
9. Flaherty LE, Redman BG, Chabot GG, et al. A phase I-II study of dacarbazine in combination with out patient interleukin-2 in metastatic malignant melanoma. Cancer 1990, 65, 2471-2477.
10. Stoter G, Ammdal S, Kodenhuis S, et al. Sequential administration of recombinant human Interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991, 9, 1687-1691.
11. Allavena P, Pirovano P, Bonazzi C, et al. In vitro and in vivo effects of cisplatin on the generation of lymphokine activated killer cells. J Natl Cancer Inst 1990, 82, 139-142.
12. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
13. Demchak PA, Mier JW, Robert NJ, et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma. A pilot study. J Clin Oncol 1991, 9, 1821-1830.
14. Legha S, Ring S, Bedikian A, et al. Biochemotherapy using Interleukin-2 + Interferon Alpha-2a in combination with Cisplatin, Vinblastine and DTIC in patients with metastatic melanoma. Melanoma Res 1993, 3, 32-36.
15. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11, 2173-2180.